<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00671398</url>
  </required_header>
  <id_info>
    <org_study_id>01-02-TL-375-023</org_study_id>
    <secondary_id>U1111-1114-8626</secondary_id>
    <nct_id>NCT00671398</nct_id>
  </id_info>
  <brief_title>Efficacy of Ramelteon on Transient Insomnia in Healthy Adults</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Single-Dose Study of TAK-375 in Healthy Adult Volunteers in a Sleep Lab Model of Transient Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Ramelteon, once daily&#xD;
      (QD), in healthy subjects within a sleep lab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insomnia is characterized by difficulties initiating and maintaining sleep, or of&#xD;
      non-restorative and non-refreshing sleep. Transient insomnia affects approximately one-third&#xD;
      to one-half of the US population, based on the results of 2 surveys of representative samples&#xD;
      of the adult US population conducted by the Gallup Organization in which respondents were&#xD;
      asked if they had &quot;ever had difficulty sleeping.&quot; Based on reports of &quot;regular&quot; or &quot;frequent&quot;&#xD;
      sleep difficulty, results from the same studies suggest that approximately one-tenth of the&#xD;
      US population experiences chronic insomnia. The ideal treatment for insomnia would reduce the&#xD;
      latency to onset of sleep and increase total sleep time, without a negative impact on sleep&#xD;
      architecture and without safety concerns or next-day effects.&#xD;
&#xD;
      Ramelteon is a selective melatonin-1 receptor agonist under global development by Takeda&#xD;
      Chemical Industries, Ltd., for the treatment of transient and chronic insomnia and for the&#xD;
      treatment of Circadian Rhythm Sleep Disorders.&#xD;
&#xD;
      This study is being conducted to evaluate the safety and efficacy of a single dose of&#xD;
      Ramelteon in normal healthy subjects in a sleep lab model of transient insomnia.&#xD;
      Participation is this study is anticipated to be about 3 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">May 2003</completion_date>
  <primary_completion_date type="Actual">May 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Latency to Persistent Sleep from 1 night of polysomnography (PSG) recording in a sleep laboratory.</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Sleep Time.</measure>
    <time_frame>Days 1 and 2.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Efficiency.</measure>
    <time_frame>Days 1 and 2.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wake Time after Persistent Sleep Onset.</measure>
    <time_frame>Days 1 and 2.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Awakenings after Persistent Sleep.</measure>
    <time_frame>Days 1 and 2.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Sleep Latency.</measure>
    <time_frame>Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Total Sleep Time.</measure>
    <time_frame>Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Sleep Quality.</measure>
    <time_frame>Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Wake Time after Sleep Onset.</measure>
    <time_frame>Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Number of Awakenings.</measure>
    <time_frame>Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Ease of Falling Back to Sleep after Awakening.</measure>
    <time_frame>Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 Nonrapid Eye Movement (NREM) Sleep</measure>
    <time_frame>Day 2.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2 Nonrapid Eye Movement (NREM) Sleep</measure>
    <time_frame>Day 2.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 3/4 Nonrapid Eye Movement (NREM) Sleep</measure>
    <time_frame>Day 2.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Latency to Rapid Eye Movement (REM) Sleep</measure>
    <time_frame>Day 2.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Total Sleep Time in REM Sleep</measure>
    <time_frame>Day 2.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">289</enrollment>
  <condition>Transient Insomnia</condition>
  <arm_group>
    <arm_group_label>Ramelteon 8 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramelteon 16 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramelteon</intervention_name>
    <description>Ramelteon 8 mg, tablets, orally for one night only.</description>
    <arm_group_label>Ramelteon 8 mg QD</arm_group_label>
    <other_name>Rozerem™</other_name>
    <other_name>TAK-375</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramelteon</intervention_name>
    <description>Ramelteon 16 mg, tablets, orally for one night only</description>
    <arm_group_label>Ramelteon 16 mg QD</arm_group_label>
    <other_name>Rozerem™</other_name>
    <other_name>TAK-375</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Ramelteon placebo-matching tablets, orally for one night only</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Females of childbearing potential who are sexually active must agree to use adequate&#xD;
             contraception, and can neither be pregnant nor lactating from Screening throughout the&#xD;
             duration of the study.&#xD;
&#xD;
          -  Habitual bedtime is between 8:30 p.m. and 12:00 a.m.&#xD;
&#xD;
          -  Sleeps 6.5 to 8 hours per night and has a subjective sleep latency of less than or&#xD;
             equal to 30 minutes.&#xD;
&#xD;
          -  Body mass index between 18 and 34, inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history of insomnia.&#xD;
&#xD;
          -  Spent one or more nights in a sleep laboratory.&#xD;
&#xD;
          -  Epworth Sleepiness Scale score of greater than 10.&#xD;
&#xD;
          -  Known hypersensitivity to Ramelteon or related compounds, including melatonin.&#xD;
&#xD;
          -  Previously participated in a study involving Ramelteon.&#xD;
&#xD;
          -  Participated in any other investigational study and/or taken any investigational drug&#xD;
             within 30 days or five half-lives prior to Day 1, whichever is longer.&#xD;
&#xD;
          -  Sleep schedule changes required by employment (ie, shift work) within three months&#xD;
             preceding Day 1 or has flown across greater than three time zones within seven days&#xD;
             prior to screening.&#xD;
&#xD;
          -  Participated in a weight loss program or substantially altered their exercise routine&#xD;
             within 30 days prior to Day 1.&#xD;
&#xD;
          -  History of seizures, sleep apnea, chronic obstructive pulmonary disease, restless leg&#xD;
             syndrome, schizophrenia, bipolar disorder, mental retardation, or cognitive disorder.&#xD;
&#xD;
          -  History of a psychiatric disorder (including anxiety or depression) within the past 12&#xD;
             months.&#xD;
&#xD;
          -  History of drug addiction or drug abuse within the past 12 months.&#xD;
&#xD;
          -  Any physical or psychiatric disorder that may be associated with sleep disturbance.&#xD;
&#xD;
          -  History of alcohol abuse within the past 12 months, as defined in Diagnostic and&#xD;
             Statistical Manual of Mental Disorders, 4th Edition Revised and/or regularly consumes&#xD;
             4 or more alcoholic drinks per day.&#xD;
&#xD;
          -  Current significant neurological, hepatic, renal, endocrine, cardiovascular,&#xD;
             gastrointestinal, pulmonary, hematologic or metabolic disease.&#xD;
&#xD;
          -  Uses tobacco products during nightly awakenings.&#xD;
&#xD;
          -  Any clinically important abnormal finding as determined by a medical history, physical&#xD;
             examination, electrocardiogram, or clinical laboratory tests, as determined by the&#xD;
             investigator.&#xD;
&#xD;
          -  Positive hepatitis panel.&#xD;
&#xD;
          -  Positive urine drug screen including alcohol at screening or a positive breathalyzer&#xD;
             test at check-in.&#xD;
&#xD;
          -  Any additional condition(s) that in the investigator's opinion would&#xD;
&#xD;
               -  affect sleep-wake function&#xD;
&#xD;
               -  prohibit the subject from completing the study&#xD;
&#xD;
               -  not be in the best interest of the subject.&#xD;
&#xD;
          -  Is required to take or continues taking any disallowed medication, prescription&#xD;
             medication, herbal treatment or over-the counter medication, including:&#xD;
&#xD;
               -  Anxiolytics&#xD;
&#xD;
               -  Hypnotics&#xD;
&#xD;
               -  Antidepressants&#xD;
&#xD;
               -  Anticonvulsants&#xD;
&#xD;
               -  Sedating H1 antihistamines&#xD;
&#xD;
               -  Systemic steroids&#xD;
&#xD;
               -  Respiratory stimulants (eg, theophylline)&#xD;
&#xD;
               -  Decongestants&#xD;
&#xD;
               -  Over-the-counter and prescription stimulants&#xD;
&#xD;
               -  Over-the-counter and prescription diet aids&#xD;
&#xD;
               -  Central nervous system active drugs&#xD;
&#xD;
               -  Narcotic analgesics&#xD;
&#xD;
               -  All beta blockers&#xD;
&#xD;
               -  St. John's Wort&#xD;
&#xD;
               -  Kava-kava&#xD;
&#xD;
               -  gingko biloba&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>VP Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://general.takedapharm.com/content/file/pi.pdf?applicationcode=ab2d7112-8eb3-465a-8fda-35018a9eafb0&amp;fileTypeCode=ROZEREMPI</url>
    <description>Rozerem Package Insert</description>
  </link>
  <results_reference>
    <citation>Zammit G, Schwartz H, Roth T, Wang-Weigand S, Sainati S, Zhang J. The effects of ramelteon in a first-night model of transient insomnia. Sleep Med. 2009 Jan;10(1):55-9. doi: 10.1016/j.sleep.2008.04.010. Epub 2008 Aug 8.</citation>
    <PMID>18691937</PMID>
  </results_reference>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>May 1, 2008</study_first_submitted>
  <study_first_submitted_qc>May 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2008</study_first_posted>
  <last_update_submitted>February 27, 2012</last_update_submitted>
  <last_update_submitted_qc>February 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insomnia</keyword>
  <keyword>Sleep Disorder</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

